Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
November 07 2018 - 4:30PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, announced
today that its Chief Executive Officer and President, Daniel White,
will present at the Stifel 2018 Healthcare Conference on Wednesday,
November 14, 2018 at 11:45 a.m. ET at the Lotte New York Palace
Hotel .
A live webcast of the presentation can be
accessed on the company’s website at www.clearsidebio.com under the
“Events & Presentations” tab in the “Investor Relations”
section. Following the conference, the presentation webcast
will be archived on the website for 30 days.
About Clearside
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye
diseases. Clearside’s proprietary suprachoroidal treatment
approach offers unprecedented access to the back of the eye where
sight-threatening disease often occurs. The company’s unique
platform for eye disease treatments is inherently flexible and
intended to work with established medicines, new formulations of
medicines, as well as future innovations. Clearside’s
pipeline includes advanced and preclinical product candidates for
serious eye diseases, including uveitis and diabetic macular edema
(“DME”). Clearside’s most advanced program is in
non-infectious uveitis and it expects to submit a New Drug
Application (“NDA”) to the U.S. Food and Drug Administration
(“FDA”) for XIPERE™ (formerly “suprachoroidal CLS-TA”) for the
treatment of macular edema associated with non-infectious uveitis
by the end of 2018. In addition, Clearside recently announced
positive topline results from a Phase 2 clinical trial of XIPERE
used with EYLEA® (aflibercept) in patients with DME.
Clearside is headquartered in Alpharetta, GA. For more
information, please visit http://www.clearsidebio.com. Follow
@clearsidebio on Twitter and Linkedin.
Contacts:
Stephen KilmerInvestor Relations(678)
430-8206stephen.kilmer@clearsidebio.com
Charles DeignanChief Financial Officer(678)
270-4005charlie.deignan@clearsidebio.com
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024